Stockscreener 앱 받기
14.88
2.04%
-0.31
시간 외 거래:
14.88
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Viridian Therapeutics (VRDN) price target decreased by 11.71% to 36.18 - MSN
Sectors Review: Is Viridian Therapeutics Inc undervalued by DCF analysisGap Down & Daily Technical Forecast Reports - baoquankhu1.vn
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $24 - Moomoo
Portfolio Recap: Will Viridian Therapeutics Inc outperform its industry peersQuarterly Trade Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (VRDN) Movement - Stock Traders Daily
Viridian Therapeutics stock is tanking. Why the drop is linked to this Amgen study. - MSN
Why is Viridian Therapeutics stock sinking Monday? - MSN
Viridian Therapeutics (VRDN) Is Down 18.4% After Strong REVEAL-1 Elegrobart TED DataWhat's Changed - Sahm
Options Flow: Can Viridian Therapeutics Inc beat the S P 500Weekly Stock Report & Weekly High Momentum Picks - baoquankhu1.vn
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
Viridian Therapeutics (VRDN) soars 5.6%: Is further upside left in the stock? - MSN
Viridian Therapeutics price target lowered to $36 from $40 at Truist - Yahoo Finance
Why is Viridian Therapeutics stock falling Monday? - MSN
Stock Market Recap: Can Viridian Therapeutics Inc stock double in the next yearBreakout Watch & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN) - Seeking Alpha
VRDN: Wedbush Maintains Rating but Lowers Price Target | VRDN St - GuruFocus
Viridian Therapeutics, Inc. (VRDN) stock price, news, quote and history - Yahoo Finance UK
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi‑Month Share Price Pullback - Yahoo Finance
Goldman Sachs Maintains Buy Rating on VRDN, Lowers Price Target - GuruFocus
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy (AMGN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN) - The Globe and Mail
VRDN: RBC Capital Lowers Price Target on Viridian Therapeutics | - GuruFocus
H.C. Wainwright reiterates Viridian stock rating citing trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Viridian stock rating citing trial data - Investing.com
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail
RBC Cuts Price Target on Viridian Therapeutics to $30 From $42, Keeps Outperform, Speculative Risk - marketscreener.com
RBC Capital cuts Viridian Therapeutic stock price target on competition By Investing.com - Investing.com Canada
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study. - Barron's
Viridian Therapeutics stock tumbles after Amgen Tepezza data By Investing.com - Investing.com Australia
Viridian Therapeutics stock tumbles after Amgen Tepezza data - Investing.com
Leerink reiterates Viridian Therapeutic stock rating after rival data By Investing.com - Investing.com Canada
Viridian Therapeutics, Inc. (VRDN) Latest Stock News & Headlines - Yahoo Finance
Viridian Therapeutics (VRDN) Shares Drop Amid Competitor's Trial Success - GuruFocus
Viridian Therapeutic stock maintained at Outperform by RBC Capital - Investing.com Canada
Why Is Viridian Therapeutics Stock Sinking Monday?Amgen (NASDAQ:AMGN), Viridian Therapeutics (NASDAQ:V - Benzinga
Viridian Shares Fall After Competing Amgen Eye Drug Performs Well - Moomoo
Viridian Therapeutics (NASDAQ:VRDN) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Stock Traders Purchase Large Volume of Put Options on Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Best Biotech Stocks To ConsiderApril 6th - MarketBeat
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Viridian Therapeutics (VRDN) slides 26.8% as investors digest Phase 3 REVEAL-1 data and reset expectations - Quiver Quantitative
Institution Moves: Is Viridian Therapeutics Inc subject to activist investor interestWeekly Risk Summary & Safe Entry Point Identification - baoquankhu1.vn
Earnings Report: Should I hold or sell Viridian Therapeutics Inc nowForecast Cut & Daily Profit Focused Stock Screening - baoquankhu1.vn
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $48 - Moomoo
VRDN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
EBIT per share of Viridian Therapeutics, Inc. – LSE:0K1R - TradingView
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics (VRDN) Is Down 32.5% After Debated Phase 3 Elegrobart DataWhat's Changed - Sahm
Viridian Therapeutics, Inc. (VRDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal? - Stocktwits
Viridian Therapeutics, Inc. (0K1R.L) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-04-02 - Seeking Alpha
Transcript : Viridian Therapeutics, Inc.Special Call - marketscreener.com
2.69%
0.25%
자본화:
|
볼륨(24시간):